Table 4 Inter-group data analysis for grip strength, coordination, fatigue, functionality and quality of life variables
Variable | Experimental group Mean ± SD | Control group Mean ± SD | Mean difference | p | CI 95% of mean difference |
|---|---|---|---|---|---|
JAMAR pre-treatment | 29.70 (± 10.66) | 21.38 (± 13.37) | 8.33 | 0.07 | − 0.72 to 17.37 |
JAMAR post-treatment | 29.66 (± 8.95) | 23.39 (± 13.19) | 6.27 | 0.14 | − 2.15 to 14.71 |
JAMAR follow-up | 31.44 (± 10.63) | 21.58 (± 12.83) | 9.87 | 0.03* | 1.04 to 18.69 |
BBT pre-treatment | 47.9 (± 10.04) | 37.67 (± 13.3) | 10.23 | 0.024* | 1.42 to 19.05 |
BBT post-treatment | 50.23 (± 11.07) | 39.17 (± 13.39) | 11.07 | 0.02* | 1.81 to 20.25 |
BBT follow-up | 52.73 (± 10.72) | 42.27 (± 13.45) | 11.47 | 0.026* | 1.37 to 19.57 |
FSS pre-treatment | 69.31 (± 20.84) | 61.8 (± 29.12) | 7.51 | 0.428 | − 11.67 to 26.71 |
FSS post-treatment | 69.42 (± 21.86) | 60.43 (± 27.21) | 8.99 | 0.334 | − 9.76 to 27.73 |
FSS follow-up | 73.86 (± 20.45) | 60.54 (± 28.55) | 13.32 | 0.158 | − 5.5 to 32.14 |
ABILHAND pre-treatment | 37.20 (± 8.08) | 32.64 (± 13.71) | 4.56 | 0.281 | − 3.95 to 13.06 |
ABILHAND post-treatment | 37.67 (± 6.44) | 34.00 (± 12.41) | 3.67 | 0.322 | − 3.79 to 11.13 |
ABILHAND follow-up | 37.07 (± 8.14) | 34.86 (± 12.29) | 2.21 | 0.57 | − 5.7 to 10.1 |
MSIS-29 PD pre− treatment | 43.67 (± 24.80) | 47.41 (± 32.79) | − 3.74 | 0.73 | − 25.8 to 18.31 |
MSIS-29 PD post-treatment | 53.67 (± 16.15) | 47.5 (± 30.52) | 6.17 | 0.498 | − 12.25 to 24.59 |
MSIS-29 PD follow-up | 52.00 (± 27.12) | 47.77 (31.15) | 4.23 | 0.699 | − 17.98 to 26.44 |
MSIS-29 CD pre-treatment | 36.66 (± 18.85) | 50.20 (± 28.06) | − 13.54 | 0.136 | − 31.64 to 4.56 |
MSIS-29 CD post-treatment | 44.06 (± 27.04) | 45.83 (± 34.40) | − 1.77 | 0.879 | − 25.25 to 21.72 |
MSIS-29 CD follow-up | 42.03 (± 28.94) | 48.21 (± 33.18) | − 6.18 | 0.597 | − 29.87 to 17.5 |